Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery

Diabetes, Obesity and Metabolism

Volumn 20, Issue 4, 2018, Pages 1018-1023

  Shah, Ankit ^a   Levesque, Kiarra ^b   Pierini, Esmeralda ^b   Rojas, Betsy ^c   Ahlers, Michael ^b   Stano, Sarah ^b   Holter, Marlena ^b   Dutia, Roxanne ^b   Belsley, Scott ^c   McGinty, James ^c   Laferrère, Blandine ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Department of Surgery   (United States)

Author keywords

dipeptidyl peptidase 4 inhibitor; gastric bypass; type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; PLACEBO; SITAGLIPTIN;

ADULT; AGE; ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LONGITUDINAL STUDY; MALE; MIXED MEAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ROUX-EN-Y GASTRIC BYPASS; SELF MONITORING; SHORT COURSE THERAPY; AGED; BLOOD; GASTRIC BYPASS SURGERY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

ADULT; AGED; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC BYPASS; GLYCATED HEMOGLOBIN A; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SITAGLIPTIN PHOSPHATE;

EID: 85043517970     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13139     Document Type: Article

References (18)

1. Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–455.
2. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30(7):1709–1716.
3. Jorgensen NB, Dirksen C, Bojsen-Moller KN, et al. Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013;62(9):3044–3052.
4. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11–12):761–765.
5. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy. 2010;30(6):609–624.
6. Alam ML, Van der Schueren BJ, Ahren B, et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):378–381.
7. Stubbs RJ, Hughes DA, Johnstone AM, et al. The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings. Br J Nutr. 2000;84(4):405–415.
8. Sigstad H. A Clinical diagnostic index in the diagnosis of the dumping syndrome. Changes in plasma volume and blood sugar after a test meal. Acta Med Scand. 1970;188(6):479–486.
9. Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care. 2007;30(7):1747–1752.
10. Kjems LL, Christiansen E, Volund A, Bergman RN, Madsbad S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes. 2000;49(4):580–588.
11. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56(5):1475–1480.
12. Svane MS, Bojsen-Moller KN, Nielsen S, et al. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. Am J Physiol Endocrinol Metab. 2016;310(7):E505–E514.
13. Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):200–207.
14. Dixon JB, Zimmet P, Alberti KG, Rubino F. International diabetes federation taskforce on E, prevention. Bariatric surgery: an IDF statement for obese type 2 diabetes. Arq Bras Endocrinol Metabol. 2011;55(6):367–382.
15. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93–102.
16. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637.
17. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(7):2479–2485.
18. Aschner P, Katzeff HL, Guo H, et al. Sitagliptin Study 049 GroupEfficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):252–261.